Yongxian Hu, Houli Zhao, Alex Hongsheng Chang, et al.
Conclusions: Our data showed BCMA CAR-T treatment is safe with prominent efficacy. We also observed high activation of BCMA CAR-T cells contribute to potent anti-myeloma activity. These initial data provide strong evidence to support the further development of this anti-myeloma cellular immunotherapy.
Ethan Thompson, Yue Jiang, Timothy Campbell, et al.
Conclusions: These data from CRB-401 led us to identify candidate drug product attributes and soluble factors that correlate with response to ide-cel. Changes in sBCMA expression may be a robust biomarker of both early and durable responses to ide-cel and the depth of clearance of sBCMA at 2 months post-infusion may be superior to standard markers for identification of patients at risk of myeloma progression. Further characterization with CyTOF and RNA sequencing could identify additional drug product attributes associated with clinical outcomes following ide-cel treatment. Validation in a larger cohort is ongoing.